Ovitrelle

DRUG4 trials

Sponsors

Hadassah Medical Organization, University Hospital, Ghent, Rigshospitalet, Denmark, Ferring Pharmaceuticals

Conditions

BRCA1 MutationBRCA2 MutationIn Vitro FertilizationInfertilityInfertility, FemaleOvarian ReservehCG

Phase 2

Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation

WithdrawnNCT05571111

Ferring PharmaceuticalsInfertility

Start: 2022-10-04End: 2024-06-25Updated: 2023-01-09

Phase 4

Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers

CompletedNCT03495609

University Hospital, GhentBRCA1 Mutation, BRCA2 Mutation, hCG

Start: 2016-02-17End: 2018-12-18Updated: 2023-09-07

hCG Priming in Women With Low Ovarian Reserve

CompletedNCT04643925

Rigshospitalet, DenmarkInfertility, Female, In Vitro Fertilization, Ovarian Reserve

Start: 2020-12-27End: 2021-08-31Updated: 2022-08-25

Unknown Phase

Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders

Hadassah Medical OrganizationInfertility

Start: 2011-04-30Target: 100Updated: 2011-03-02

Related Papers

Androgen and inhibin B levels during ovarian stimulation before and after 8 weeks of low-dose hCG priming in women with low ovarian reserve

Human Reproduction2023-06-243 citations

P-682 Androgen and Inhibin B levels during ovarian stimulation before and after eight weeks of low dose hCG priming in women with low ovarian reserve

Human Reproduction2023-06-01

Eight weeks of androgen priming by daily low-dose hCG injections before ICSI treatment in women with low ovarian reserve

Human Reproduction2023-01-317 citations

P-626 Eight weeks of androgen priming by low dose hCG before IVF/ICSI in women with low ovarian reserve

Human Reproduction2022-06-29